Serum bilirubin ? 1.5 x ULN, except in subjects with Gilbert's Syndrome who must have a total bilirubin < 3 mg/dL
Total bilirubin =< 1.5 mg/dL (=< 2.0 in patients with known Gilbert's syndrome)
Serum bilirubin <1.5 mg/dL (except subjects with Gilbert's syndrome who may have total bilirubin <3.0 mg/mL)
Obtained within 14 days prior to C1D1: Total Bilirubin =< 1.5 x ULN, except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL
Bilirubin ?2 x ULN (except subjects with Gilbert's syndrome, who must have total bilirubin < 3.0 mg/dL (<52 µmol/L))
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who must have total bilirubin < 3.0 mg/dL) within 14 days prior to first dose of protocol-indicated treatment.
Within 14 days of the first dose of study drug: Total bilirubin =< 1.5 x ULN (except patients with Gilbert syndrome who must have total bilirubin < 3.0 mg/dL)
Bilirubin =< 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL).
Total Serum Bilirubin ? 1.5 x ULN (< 3.0 mg/dL if subject has Gilbert's syndrome)
Obtained within 14 days prior to randomization/registration: total Bilirubin =< 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin ? 1.5 mg/dl, except in subjects with Gilbert's syndrome.
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) within 14 days of registration
Total bilirubin =< 2 mg/dL or direct bilirubin =< ULN for those with total bilirubin > 2 x ULN; subjects with Gilbert syndrome will be eligible if total bilirubin is < 3.0 mg/dL
Total bilirubin =< 1.5 x ULN within 14 days of study registration (except subjects with Gilbert Syndrome who must have total bilirubin < 3.0 mg/dl).
Obtained within 21 days prior to randomization/registration: Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL).
Bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin (Bili T) =< 1.5 x ULN (although patients with Gilbert syndrome can have total bilirubin < 3.0 mg/dL), within 30 days before study registration
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL) within 14 days prior to first dose
Serum total bilirubin =< 1.5 x ULN (subjects with Gilbert syndrome can have a total bilirubin < 3 mg/dL), performed within 14 days of protocol registration
Obtained within 14 days of randomization: Total bilirubin =< 1.5 x ULN (except subjects with Gilbert Syndrome who must have total bilirubin < 3.0 mg/dL)
Total bilirubin > 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Serum total bilirubin =< 1.5 X ULN OR except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL) or =< 2 x ULN if lenalidomide is being prescribed; should be obtained within 21 days prior to enrollment
Bilirubin ? 2.0 x ULN, (except patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
Total Bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin =< 2 mg/dL, except for patient's with Gilbert's syndrome
Total bilirubin =< 1.5 mg/dL x upper limit of normal (ULN) (except subjects with Gilbert syndrome who can have total bilirubin =< 3.0 mg/dL)
Total bilirubin =< 1.5 x ULN; except subjects with Gilbert syndrome who can have total bilirubin < 3.0 mg/dL) obtained within 14 days of first treatment
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL) obtained within 14 days prior to randomization/registration
Bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilbert's syndrome who must have a total bilirubin less than 3.0 mg/dl (Turnstile II - Chemotherapy/Cell Infusion - Inclusion Criteria)
Total bilirubin ? 2 mg/dL (except in patients with Gilbert's Syndrome)
Total bilirubin ? 2 mg/dL (except in patients with Gilbert's Syndrome)
Total bilirubin ? 1.5 × (< 3 mg/dL for subjects with Gilbert's disease)
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Obtained within 30 days prior to registration: Bilirubin 1.5 =< (ULN)\r\n* Except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL
Bilirubin =< 1.5 mg/dl, in patients with Gilbert's syndrome, a total bilirubin =< 3.0 mg/dL
Total bilirubin less than or equal to 2.0 mg/dL, except in patients with Gilbert's syndrome who must have a total bilirubin less than 3.0 mg/dL
Total bilirubin less than or equal to 2.0 mg/dL, except in patients with Gilbert's syndrome who must have a total bilirubin less than 3.0mg/dL
Serum total bilirubin < 2 mg/dl; patients with Gilbert syndrome are excluded from the requirement of a normal bilirubin
Bilirubin =< 2 x ULN (except subjects with Gilbert syndrome who must have total bilirubin < 3.0 mg/dL)
Bilirubin less than 1.5 mg/dL; (except in patients with Gilbert's syndrome, who must have a total bilirubin less than 3.0 mg/dL)
Serum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome
Bilirubin within normal limits (except subjects with Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL)
Bilirubin =< 1.5 x ULN; for patients with Gilbert's syndrome, bilirubin =< 3.0 mg/dL is acceptable
Total bilirubin ? 3 x ULN, (except patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert Syndrome who must have total bilirubin < 3.0 mg/dL)
Total bilirubin > 2.0 mg/dl, except in patients with Gilbert's syndrome whose total bilirubin must not exceed 3.0 mg/dl) deemed by investigator to be irreversible
Total bilirubin > 2.0 mg/dl, except in patients with Gilbert's syndrome whose total bilirubin must not exceed 3.0 mg/dl)
Total bilirubin =< 1.5 x ULN (< 3 mg/dL for subjects with Gilbert's disease)
Total Serum Bilirubin ? 1.5 x ULN (< 3.0 mg/dL if subject has Gilbert's syndrome)
Total bilirubin ? 1.5 × ULN (except in patients with Gilbert Syndrome who can have total bilirubin < 3.0 mg/dL).
Serum bilirubin ? 1.5 x ULN, except in patients with Gilbert's Syndrome who must have a total bilirubin < 3 mg/dL
Total bilirubin =< ULN (except subjects with Gilbert syndrome who must have total bilirubin < 3.0 mg/dl)
Serum total bilirubin < 2 x ULN (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Bilirubin =< 2.0 x ULN, (except patients with Gilbert's syndrome, who must have a total bilirubin less than 3.0 mg/dL)
COHORT A: Bilirubin =< 1.5 x ULN (except patients with Gilbert's syndrome, who must have a total bilirubin less than 3.0 mg/dL)
COHORT B: Bilirubin =< 1.5 x ULN (except patients with Gilbert's syndrome, who must have a total bilirubin less than 3.0 mg/dL)
Bilirubin =< 1.5 mg/dL (OR in patients with Gilbert's syndrome, a total bilirubin =< 3.0) (within 16 days before starting therapy)
Total Bilirubin >1.5x ULN (except subjects with Gilbert syndrome, total bilirubin <3.0 mg/dL)
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin ?1.5 x ULN, except in patients with Gilbert's Syndrome who must have a total bilirubin <3 mg/dL (51.3 ?mol/L)
Total bilirubin <1.5 x ULN, except for patients with Gilbert's disease who are eligible if total bilirubin ? 3mg/dL.
Adequate hepatic and renal function laboratory values within 14 days prior to registration: Total bilirubin =< 1.5 mg/dL except for patients with a history of elevated total bilirubin, such as in Gilbert's
Serum total bilirubin >2.0 mg/dL (with the exception of Gilbert's Syndrome)
Total bilirubin =< 3 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Serum total bilirubin < 2 mg/dl; patients with Gilbert syndrome are excluded from the requirement of a normal bilirubin
Total bilirubin < 1.5 x ULN (except subjects with Gilbert syndrome who can have total bilirubin < 3.0 mg/deciliter) should be obtained with 28 days prior to randomization
Total bilirubin <1.5 mg/dl, except in subjects with Gilbert's syndrome
Total bilirubin >ULN: Subjects with Gilbert's syndrome are allowed if total bilirubin is <3.0 mg/dL and direct bilirubin is ?ULN,
Bilirubin less than 1.5 mg/dL; (except in patients with Gilbert's syndrome, who must have a total bilirubin less than 3.0 mg/dL)
Bilirubin =< 3.0 x ULN (except patients with Gilbert's syndrome, who must have a total bilirubin less than 3.0 mg/dL)
Total bilirubin =< 1.5 x ULN; (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin ? 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
T. bilirubin < 2 mg/dl (Patients with Gilbert Syndrome total bilirubin <3xULN and direct bilirubin ? 35%)
Serum total bilirubin ? 2.5 mg/dL (43 ?mol/L), except for subjects with Gilbert's syndrome.
Total bilirubin =< 2.0 mg/dL (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)